KOL Identification

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A leader in synthetic oligonucleotide manufacturing wanted to assess the total market size and opportunity

A leading pharmaceutical & clinical diagnostics manufacturer wanted to understand the market opportunity for a novel multidisciplinary cancer conference IT support solution

A top-10 diagnostics company wanted to gauge preparedness and reactions to implementation of IVDR, and how that would impact a potential new product

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A multinational pharmaceutical and diagnostics company was interested in learning more about the U.S. market opportunity for their novel noninvasive prenatal test in development